Structure Therapeutics Inc. (GPCR)
GPCR moved a median of -0.29% 30 minutes after news, and -1.28% by the close. How GPCR actually reacts to news — the realized, point-in-time move the market made, measured across 242 labeled events over the last three years with zero look-ahead.
GPCR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.21% | 40% | 241 |
| 30-min | -0.29% | 43% | 242 |
| 60-min | -0.57% | 43% | 242 |
| to close | -1.28% | 42% | 238 |
| Middle 50% of GPCR reactions | -2.13% to +0.84% |
|---|---|
| Median reaction (30-min) | -0.29% |
| Measured reactions | 242 |
Half of all Structure Therapeutics Inc. news events land between -2.13% and +0.84% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How GPCR reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 30 | -2.21% | 13% | -2.90% |
| Rating reiterations | 83 | -0.05% | 49% | -0.56% |
| Price-target raises | 10 | -0.34% | 50% | +0.47% |
| Price-target cuts | 10 | -1.21% | 30% | -1.40% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how GPCR ranks against every other measured name →
That’s how GPCR usually reacts — get an email when it moves on news →Email me when GPCR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to GPCR's baseline. Nothing else.
Recent GPCR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Structure Therapeutics For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | -4.78% | -13.79% | |
| Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management | Press release | GlobeNewswire | -4.78% | -13.79% | |
| Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences | Press release | GlobeNewswire | -0.50% | -1.80% | |
| Form 10-Q Structure Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.99% | -1.45% | |
| Form 8-K Structure Therapeutics For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -0.99% | -1.45% | |
| Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights | Press release | GlobeNewswire | -0.99% | -1.45% | |
| MEDIA INVITE: A Conversation on Bias and Lived Experience | Press release | PR Newswire | -0.86% | -5.89% | |
| Kinaset Therapeutics Appoints Daniel G. Welch as Board Chair and David Lubner as Independent Director and Audit Committee Chair | Press release | Business Wire | +2.31% | +3.83% | |
| Form 8-K Structure Therapeutics For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +3.12% | +2.27% | |
| Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity | Press release | GlobeNewswire | +2.76% | +0.80% | |
| Structure Therapeutics Announces Participation in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.80% | -0.90% | |
| Obesity Action Coalition Extends Early Bird Pricing for the Your Weight Matters National Convention Through June 22 | Press release | PR Newswire | +0.18% | -0.03% | |
| Form 10-Q Structure Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.54% | +2.46% | |
| Form 8-K Structure Therapeutics For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +2.54% | +2.46% | |
| Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights | Press release | GlobeNewswire | +2.54% | +2.46% | |
| FormBlends Publishes 2026 State of Peptides Report as RFK-Era HHS Signals Major Shifts for GLP-1 and Peptide Therapy Access in the United States | Press release | GlobeNewswire | +0.56% | -3.26% | |
| Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions | Press release | GlobeNewswire | +0.56% | -3.26% | |
| Form ARS Structure Therapeutics For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.01% | -3.21% | |
| Form DEF 14A Structure Therapeutics For: Jun 17 | SEC filing · Form DEF | SEC EDGAR | -0.01% | -3.21% | |
| Form 8-K Structure Therapeutics For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | -0.01% | +2.86% | |
| Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | Press release | GlobeNewswire | -0.01% | +2.86% | |
| Form 8-K Structure Therapeutics For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | -2.26% | +0.12% | |
| Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron | Press release | GlobeNewswire | -2.26% | +0.12% | |
| Form 10-K Structure Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.97% | -1.79% | |
| Form 8-K Structure Therapeutics For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | +0.97% | -1.79% | |
| Form S-8 Structure Therapeutics | SEC filing · Form S-8 | SEC EDGAR | +0.97% | -1.79% | |
| Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights | Press release | GlobeNewswire | +0.97% | -1.79% | |
| Form 8-K Structure Therapeutics For: Dec 30 | SEC filing · Form 8-K | SEC EDGAR | +0.79% | -0.25% | |
| Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | Press release | GlobeNewswire | +0.33% | -2.49% | |
| Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs | Press release | GlobeNewswire | -1.18% | -2.26% | |
| Form 8-K Structure Therapeutics For: Dec 09 | SEC filing · Form 8-K | SEC EDGAR | +1.29% | -2.68% | |
| Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants | Press release | GlobeNewswire | +1.28% | +2.90% | |
| Form 8-K Structure Therapeutics For: Dec 08 | SEC filing · Form 8-K | SEC EDGAR | +17.11% | +54.93% | |
| Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants | Press release | GlobeNewswire | +1.08% | -2.13% | |
| Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron | Press release | GlobeNewswire | +17.11% | +54.93% | |
| Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025 | Press release | GlobeNewswire | +17.11% | +54.93% | |
| Form 10-Q Structure Therapeutics For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.22% | -2.55% | |
| Form 8-K Structure Therapeutics For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -1.22% | -2.55% | |
| Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights | Press release | GlobeNewswire | -1.22% | -2.55% | |
| Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences | Press release | GlobeNewswire | +3.02% | +4.58% | |
| Form 10-Q Structure Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.37% | -8.42% | |
| Form 8-K Structure Therapeutics For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -2.37% | -8.42% | |
| Form S-3ASR Structure Therapeutics | SEC filing · Form S-3ASR | SEC EDGAR | -2.37% | -8.42% | |
| Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights | Press release | GlobeNewswire | -2.37% | -8.42% | |
| Form 8-K Structure Therapeutics For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | +0.67% | -2.99% | |
| Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671 | Press release | GlobeNewswire | -1.28% | +0.87% | |
| Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences | Press release | GlobeNewswire | -2.41% | -3.03% | |
| Form 10-Q Structure Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.30% | -4.05% | |
| Form 8-K Structure Therapeutics For: May 08 | SEC filing · Form 8-K | SEC EDGAR | -0.30% | -4.05% | |
| Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights | Press release | GlobeNewswire | -0.30% | -4.05% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the GPCR section they belong to.
Where else GPCR is measured.
GPCR earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Structure Therapeutics Inc.'s median reaction calculated?
Every labeled GPCR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 242 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of GPCR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does GPCR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.